RxDoctor Payments Data

Mamerto Lebita, MD

Family Medicine · Aston, PANPI 1538198353

Payments from drug & device makers

$3,893in general payments, 2019–2025

Across 208 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$691
  • AstraZeneca$666
  • Pfizer$499
  • AbbVie$318
  • Astellas Pharma US Inc$244
  • Amgen$185
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,80898%
  • Education$852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,893 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$64,054
Medicare patients
135
Services billed
694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a13$105,956
EliquisApixaban114$91,102
Trelegy ElliptaFluticasone/Umeclidin/Vilanter100$71,564
JanuviaSitagliptin Phosphate57$62,848
OzempicSemaglutide49$48,474
TradjentaLinagliptin56$46,405
TrulicityDulaglutide41$40,577
LinzessLinaclotide64$37,786
Breztri AerosphereBudesonide/Glycopyr/Formoterol59$37,074
XareltoRivaroxaban42$33,026
JanumetSitagliptin Phos/Metformin Hcl47$29,468
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$25,225
Oxycodone Hcl776$15,670
OxycontinOxycodone Hcl31$15,273
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$13,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr, Dulera$174$103,250129 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$691$99,631160 claims
PfizerEliquis$499$91,102114 claims
Boehringer IngelheimTradjenta, Spiriva Respimat, Combivent Respimat$23$62,85688 claims
AstraZenecaBreztri Aerosphere, Brilinta, Symbicort$666$55,329111 claims
Novo NordiskOzempic$101$48,47449 claims
Lilly USA, LLCTrulicity$158$40,57741 claims
AbbVieLinzess$318$37,78664 claims
Johnson & JohnsonXarelto$94$33,02642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Aston

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →